Biomedical subjects
F Miki
Publications and source records attributed to F Miki.
[Laboratory and clinical studies on minocycline].
Explore the source record for details and available documents.
[Nursing education as seen by a physician].
Explore the source record for details and available documents.
[Forum: theory of obstetrical nursing].
Explore the source record for details and available documents.
[Laboratory and clinical studies on Hetacillin].
Explore the source record for details and available documents.
[Clinical experience in use of lincomycin in internal medicine. 2].
Explore the source record for details and available documents.
[Basic and clinical studies on methyldichlorophenylisoxazolyl penicillin (staphcillin A)].
Explore the source record for details and available documents.
[Basic and clinical studies on acetylspiramycin].
Explore the source record for details and available documents.
[Resistant streptococcal infections].
Explore the source record for details and available documents.
Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method.
In a double-blind study, the efficacy and safety of the novel cephem antibiotic cefcapene pivoxil (CFPN-PI; 450 mg/day) was compared with cefteram pivoxil (CFTM-PI; 600 mg/day) in 171 patients with chronic respiratory tract infections. There was no significant difference between the clinical efficacy of the two drugs (80.2% for CFPN-PI versus 78.9% for CFTM-PI). There was no significant difference in the rate of elimination of the causative bacteria (60.5% for CFPN-PI versus 65.9% for CFTM-PI). Side-effects were observed in 6.0% of patients treated with CFPN-PI compared with 6.4% of patients treated with CFTM-PI. There were no significant differences in incidence of abnormal laboratory findings following treatment with the two drugs (13.9% for each), and none of the side-effects was severe. We conclude that CFPN-PI (450 mg/day) was as effective and as well tolerated as CFTM-PI (600 mg/day) in the treatment of chronic respiratory tract infections.